<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006988" GROUP_ID="ENDOC" ID="178305021509504875" MERGED_FROM="" MODIFIED="2008-11-11 17:51:57 +0100" MODIFIED_BY="Bernd Richter" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 17:50:17 +0100" NOTES_MODIFIED_BY="Bernd Richter" REVIEW_NO="01" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="2.0">
<COVER_SHEET MODIFIED="2008-11-11 17:51:57 +0100" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2008-10-16 14:24:29 +0200" MODIFIED_BY="Gudrun Paletta">Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases</TITLE>
<CONTACT MODIFIED="2008-11-11 17:51:57 +0100" MODIFIED_BY="Bernd Richter"><PERSON ID="8D58FF4F82E26AA201ACDCB9D348EBA5" ROLE="AUTHOR"><FIRST_NAME>Chao</FIRST_NAME><LAST_NAME>Ma</LAST_NAME><EMAIL_1>machaopony@hotmail.com</EMAIL_1><MOBILE_PHONE>+86 13156278801</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Nuclear Medicine       </DEPARTMENT><ORGANISATION>Affiliated Hospital of Medical College Qingdao University</ORGANISATION><ADDRESS_1>Jiangsu Road 16</ADDRESS_1><CITY>Qingdao</CITY><ZIP>266003</ZIP><REGION>Shandong Province</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 288 5422400</PHONE_1><PHONE_2>+86 532 2911534 </PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-11 17:51:57 +0100" MODIFIED_BY="Bernd Richter"><PERSON ID="8D58FF4F82E26AA201ACDCB9D348EBA5" ROLE="AUTHOR"><FIRST_NAME>Chao</FIRST_NAME><LAST_NAME>Ma</LAST_NAME><EMAIL_1>machaopony@hotmail.com</EMAIL_1><MOBILE_PHONE>+86 13156278801</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Nuclear Medicine       </DEPARTMENT><ORGANISATION>Affiliated Hospital of Medical College Qingdao University</ORGANISATION><ADDRESS_1>Jiangsu Road 16</ADDRESS_1><CITY>Qingdao</CITY><ZIP>266003</ZIP><REGION>Shandong Province</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 288 5422400</PHONE_1><PHONE_2>+86 532 2911534 </PHONE_2></ADDRESS></PERSON><PERSON ID="6A5C80B882E26AA200DE99846D0508A2" ROLE="AUTHOR"><FIRST_NAME>Anren</FIRST_NAME><LAST_NAME>Kuang</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>Kuanganren@263.net</EMAIL_1><ADDRESS><DEPARTMENT>Department of Nuclear Medicine</DEPARTMENT><ORGANISATION>The First Affiliated Hospital / West China University of Medical Sciences</ORGANISATION><CITY>Chengdu</CITY><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="28028C4082E26AA200831C19BEFEC1B3" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jiawei</FIRST_NAME><LAST_NAME>Xie</LAST_NAME><EMAIL_1>xiejiawei@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Stomatology</DEPARTMENT><ORGANISATION>Affiliated Hospital </ORGANISATION><ADDRESS_1>Jiangsu Road 16</ADDRESS_1><CITY>Qingdao</CITY><ZIP>266003</ZIP><REGION>Shandong</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 532-82911213</PHONE_1><PHONE_2>+86 13669916279</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-05 12:27:22 +0100" MODIFIED_BY="Bernd Richter">
<UP_TO_DATE>
<DATE DAY="31" MONTH="5" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-11 17:43:48 +0100" MODIFIED_BY="Bernd Richter">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-11 17:43:48 +0100" MODIFIED_BY="Bernd Richter">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-05 12:27:40 +0100" MODIFIED_BY="Bernd Richter"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-11 17:50:17 +0100" MODIFIED_BY="Bernd Richter">
<SUMMARY MODIFIED="2008-11-05 16:14:42 +0100" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2008-11-05 12:16:35 +0100" MODIFIED_BY="Bernd Richter">Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-05 16:14:42 +0100" MODIFIED_BY="Bernd Richter">
<P>The main method for the treatment of differentiated thyroid carcinomas (a cancer of the thyroid gland) is total or near-total thyroidectomy (surgical removal of the thyroid) followed by radioactive iodine therapy (iodine-131) and treatment with thyroid hormones (mainly thyroxin). The metastatic disease of this thyroid carcinoma or spread of the tumour includes local recurrence and distant metastases. Metastatic disease is a factor that worsens prognosis of patients with differentiated thyroid carcinoma. After surgery or as the primary treatment, located metastases should, if possible, be removed by an experienced surgeon. For unremovable metastases which can gather radioiodine, iodine-131 therapy is an accepted procedure.</P>
<P>Differentiated thyroid carcinoma is typically able to produce thyroglobulin, the protein in the thyroid gland from which the thyroid hormones thyroxine and triiodotyrosine are synthesized, and gather radioiodine. Thyroglobulin is produced only by thyroid cells. If all normal and malignant thyroid tissue is successfully removed, any thyroglobulin subsequently detected in a patient with differentiated thyroid carcinoma is thought to be the product of recurrent malignancy. Thus, radioiodine diagnostic whole-body scanning and measurement of serum thyroglobulin levels are the two main methods for detecting metastatic disease of differentiated thyroid carcinoma. Undetectable thyroglobulin levels with negative radioiodine whole body scan suggest complete remission, whereas detectable or elevated thyroglobulin is associated with the presence of radioiodine uptake in local or distant metastases.</P>
<P>Up to now, to treat or not to treat these patients who have thyroglobulin positive and radioactive iodine negative metastases with radioiodine remains controversial. Some doctors advocate blind iodine-131 treatment for thyroglobulin positive and radioactive iodine negative metastases. Radioiodine therapy may be especially justified in patients with higher thyroglobulin levels (greater than 10 mg/L) and negative iodine-131 whole body scan and who are at high risk of any recurrence. However, high-dose radioactive iodine therapy is not without risk; especially an increased prevalence of cancers of the bladder, salivary gland, colon and female breast has been reported.</P>
<P>Unfortunately, no firm evidence from randomised or prospective controlled trials for or against radioiodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases could be found. Further prospective controlled trials of high-quality and large scale are needed to guide clinical practice.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-05 14:42:58 +0100" MODIFIED_BY="Bernd Richter">
<ABS_BACKGROUND MODIFIED="2008-11-05 14:39:03 +0100" MODIFIED_BY="Bernd Richter">
<P>Differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases has been observed in follow-up studies. The management of this condition remains controversial. Most studies support blind radioactive iodine treatment while others negate this approach.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-05 12:25:45 +0100" MODIFIED_BY="Bernd Richter">
<P>Studies were obtained from computerised searches of MEDLINE, EMBASE, <I>The Cochrane Library</I>, China National Infrastructure (CNKI) and paper collections of conferences held in Chinese.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled clinical trials and prospective controlled clinical trials.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-05 14:40:43 +0100" MODIFIED_BY="Bernd Richter">
<P>Two authors independently extracted data and interviewed authors of all potentially relevant studies by electronic mail to verify randomisation procedures. One author entered data into a data extraction form and the second one verified the results of this procedure.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-05 14:42:10 +0100" MODIFIED_BY="Bernd Richter">
<P>Because of the absence of any suitable randomised or prospective controlled trial in this area, results currently cannot be presented.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-05 14:42:58 +0100" MODIFIED_BY="Bernd Richter">
<P>The currently available evidence is insufficient to reliably assess the potential of radioiodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-11 17:50:17 +0100" MODIFIED_BY="Bernd Richter">
<BACKGROUND MODIFIED="2008-11-05 15:37:52 +0100" MODIFIED_BY="Bernd Richter">
<CONDITION MODIFIED="2008-11-05 15:16:09 +0100" MODIFIED_BY="Bernd Richter">
<SUBSECTION>
<HEADING LEVEL="3">Metastatic disease of differentiated thyroid carcinoma</HEADING>
<P>Clinically detectable thyroid carcinomas constitute less than one percent of all human cancers. The annual incidence rate of thyroid cancers in various parts of the world ranges from 0.5 to 10 cases per 100,000 population (<LINK REF="REF-Schlumberger-1998" TYPE="REFERENCE">Schlumberger 1998</LINK>). Most thyroid cancers are differentiated papillary or follicular carcinomas arising from follicular cells. The predominant method for treatment of differentiated thyroid carcinomas is total or near-total thyroidectomy followed by iodine-131 remnant ablation and thyroxin therapy (<LINK REF="REF-Holzer-2000" TYPE="REFERENCE">Holzer 2000</LINK>; <LINK REF="REF-Hundahl-2000" TYPE="REFERENCE">Hundahl 2000</LINK>). Metastatic disease of differentiated thyroid carcinoma includes local recurrence and distant metastases. Metastatic disease is a factor that worsens prognosis of patients with differentiated thyroid carcinoma. Fortunately, differentiated thyroid carcinoma has an excellent prognosis, despite the presence of lymph-node metastases in 5% to 20% of patients and distant metastases in 10% to 15%. Ten-year survival is 80% to 95% (<LINK REF="REF-Mackenzie-2004" TYPE="REFERENCE">Mackenzie 2004</LINK>). After surgery or as the primary treatment, the metastases of differentiated thyroid carcinoma should be debulked by an experienced surgeon, where practical. For unresectable metastases which can accumulate radioiodine, iodine-131 therapy has been a commonly accepted procedure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Detection of metastatic disease of differentiated thyroid carcinoma</HEADING>
<P>Patients with differentiated thyroid carcinoma are at a high risk of local recurrence and distant metastases. Therefore, it is essential to carry out a long-term follow-up throughout the patient's life. Differentiated thyroid carcinoma is typically well differentiated to be able to synthesize thyroglobulin, the protein in the thyroid gland from which the thyroid hormones thyroxine and triiodotyrosine are synthesized, and accumulate radioiodine. Thus, radioiodine diagnostic whole-body scanning and measurement of serum thyroglobulin levels are the two main methods for detecting metastatic disease of differentiated thyroid carcinoma. Generally, thyroglobulin and iodine-131 whole body scan, two 'markers' of differentiated thyroid carcinoma when utilized at the same time, are usually correlated with each other in follow-up studies (<LINK REF="REF-Ozata-1994" TYPE="REFERENCE">Ozata 1994</LINK>; <LINK REF="REF-Pacini-1999" TYPE="REFERENCE">Pacini 1999</LINK>). Undetectable thyroglobulin levels with negative radioiodine whole body scan suggest complete remission, whereas detectable or elevated thyroglobulin is associated with the presence of radioiodine uptake in local or distant metastases.</P>
<P>About 10% to 15% thyroglobulin positive and radioactive iodine negative metastases have been reported in large series (<LINK REF="REF-Brendel-1990" TYPE="REFERENCE">Brendel 1990</LINK>; <LINK REF="REF-De-Keizer-2001" TYPE="REFERENCE">De Keizer 2001</LINK>; <LINK REF="STD-Koh-2003" TYPE="STUDY">Koh 2003</LINK>; <LINK REF="REF-Mazzaferri-2001" TYPE="REFERENCE">Mazzaferri 2001</LINK>; <LINK REF="REF-Mertens-1999" TYPE="REFERENCE">Mertens 1999</LINK>; <LINK REF="REF-Muller_x002d_Gartner-1988" TYPE="REFERENCE">Muller-Gartner 1988</LINK>; <LINK REF="STD-Pacini-2001" TYPE="STUDY">Pacini 2001</LINK>; <LINK REF="REF-Pineda-1995" TYPE="REFERENCE">Pineda 1995</LINK>; <LINK REF="REF-Schlumberger-1997" TYPE="REFERENCE">Schlumberger 1997</LINK>). Differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases may result from the hypothesis that thyroglobulin synthesis and radioiodine uptake reflect different functions of thyroid tissues. The serum thyroglobulin levels may not predict radioiodine uptake, nor does radioiodine uptake predict thyroglobulin levels (<LINK REF="REF-Ozata-1994" TYPE="REFERENCE">Ozata 1994</LINK>). For example, Hurthle cell carcinomas may be able to synthesize thyroglobulin but have poor radioiodine uptake capability (<LINK REF="REF-Stojadinovic-2001" TYPE="REFERENCE">Stojadinovic 2001</LINK>). Radioactive iodine negative metastases may be due to the loss of differentiation, or dispersed microscopic metastases which are too small to be visualized (<LINK REF="REF-Chao-2005_x002d_1" TYPE="REFERENCE">Chao 2005-1</LINK>; <LINK REF="REF-Fatourechi-2000" TYPE="REFERENCE">Fatourechi 2000</LINK>; <LINK REF="REF-Sherman-1994" TYPE="REFERENCE">Sherman 1994</LINK>) or improper patient preparation before radioiodine whole body scan. For a detailed overview of differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases, readers are referred to Chao et al (<LINK REF="REF-Chao-2005_x002d_1" TYPE="REFERENCE">Chao 2005-1</LINK>; <LINK REF="REF-Chao-2005_x002d_2" TYPE="REFERENCE">Chao 2005-2</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2008-11-05 15:26:24 +0100" MODIFIED_BY="Bernd Richter">
<P>Radioiodine is a &#946;-, &#947;-emitting radionuclide with a physical half-life of 8.1 days, a principal &#947;-ray of 364 keV, and a principal &#946;-particle with a maximum energy of 0.61 Mev, an average energy of 0.192 Mev, and a range in tissue of 0.8 mm. At present, iodine-131 is the most commonly used radioactive iodine for the management of metastatic disease of differentiated thyroid cancer (<LINK REF="REF-Schlumberger-1998" TYPE="REFERENCE">Schlumberger 1998</LINK>). Therapy is applied through oral administration of iodine-131 as sodium iodide.</P>
<P>Up to now, to treat or not to treat these patients who have thyroglobulin positive and radioactive iodine negative metastases with radioiodine remains controversial (<LINK REF="REF-Fatourech-2002" TYPE="REFERENCE">Fatourech 2002</LINK>; <LINK REF="REF-McDougall-1997" TYPE="REFERENCE">McDougall 1997</LINK>; <LINK REF="STD-Pacini-2001" TYPE="STUDY">Pacini 2001</LINK>; <LINK REF="REF-Samaan-1985" TYPE="REFERENCE">Samaan 1985</LINK>). Thyroglobulin is produced only by thyroid follicular cells. If all normal and malignant thyroid tissue is successfully ablated, any thyroglobulin subsequently detected in a patient with differentiated thyroid carcinoma can only be the product of recurrent malignancy. This concept led to the initial studies that indicated the usefulness of isolated and serial serum thyroglobulin determinations as a marker for differentiated thyroid carcinoma and as an indicator of the effect of surgical and iodine-131 therapy (<LINK REF="REF-Clark-2002" TYPE="REFERENCE">Clark 2002</LINK>; <LINK REF="REF-Spencer-1996" TYPE="REFERENCE">Spencer 1996</LINK>). Therefore, some researchers (<LINK REF="REF-De-Keizer-2001" TYPE="REFERENCE">De Keizer 2001</LINK>; <LINK REF="STD-Koh-2003" TYPE="STUDY">Koh 2003</LINK>; <LINK REF="REF-Pacini-1987" TYPE="REFERENCE">Pacini 1987</LINK>; <LINK REF="REF-Pineda-1995" TYPE="REFERENCE">Pineda 1995</LINK>; <LINK REF="REF-Schlumberger-1988" TYPE="REFERENCE">Schlumberger 1988</LINK>; <LINK REF="STD-Tian-2003" TYPE="STUDY">Tian 2003</LINK>; <LINK REF="REF-Van-Tol-2003" TYPE="REFERENCE">Van Tol 2003</LINK>) advocate blind iodine-131 treatment for thyroglobulin positive and radioactive iodine negative metastases based on the improvement in various parameters of disease activity, such as significant reduction of serum thyroglobulin and the detection of neoplastic foci not seen with diagnostic doses of iodine-131. However, a low or even undetectable thyroglobulin offers no guarantee for the absence of recurrent or metastatic disease (<LINK REF="REF-Brendel-1990" TYPE="REFERENCE">Brendel 1990</LINK>; <LINK REF="REF-Maxon-1983" TYPE="REFERENCE">Maxon 1983</LINK>).</P>
<P>When thyroglobulin level is considered as an index of tumour burden, a decreased thyroglobulin level in 63% of patients with thyroglobulin positive and radioactive iodine negative metastases and the 62% positive post-therapy whole-body scanning results suggest a therapeutic effect of iodine-131. Therefore, radioiodine therapy may be justified in patients with thyroglobulin levels of greater than 10 mg/L and negative iodine-131 diagnostic whole body scan and who are at high risk of any recurrence (<LINK REF="REF-Chao-2005_x002d_2" TYPE="REFERENCE">Chao 2005-2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of the intervention</HEADING>
<P>Risks for differentiated thyroid carcinoma-related morbidity or mortality have not been well described, particularly for patients without evidence of tumour mass by other imaging modalities (<LINK REF="REF-Alexande-1998" TYPE="REFERENCE">Alexande 1998</LINK>). Furthermore, high-dose radioactive iodine therapy is not without risk. An increased prevalence of cancers of the bladder, salivary gland, colon (<LINK REF="REF-de-Vathaire-1997" TYPE="REFERENCE">de Vathaire 1997</LINK>), and female breast has been reported.</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2008-11-05 15:29:58 +0100" MODIFIED_BY="Bernd Richter">
<P>Some authors (<LINK REF="REF-Cailleux-2000" TYPE="REFERENCE">Cailleux 2000</LINK>; <LINK REF="REF-De-Keizer-2001" TYPE="REFERENCE">De Keizer 2001</LINK>; <LINK REF="STD-Koh-2003" TYPE="STUDY">Koh 2003</LINK>; <LINK REF="REF-Mazzaferri-2001" TYPE="REFERENCE">Mazzaferri 2001</LINK>; <LINK REF="REF-Pacini-1987" TYPE="REFERENCE">Pacini 1987</LINK>; <LINK REF="REF-Pineda-1995" TYPE="REFERENCE">Pineda 1995</LINK>; <LINK REF="REF-Schlumberger-1997" TYPE="REFERENCE">Schlumberger 1997</LINK>; <LINK REF="STD-Tian-2003" TYPE="STUDY">Tian 2003</LINK>; <LINK REF="REF-Tenenbaum-1996" TYPE="REFERENCE">Tenenbaum 1996</LINK>; <LINK REF="REF-Van-Tol-2003" TYPE="REFERENCE">Van Tol 2003</LINK>) are in favour of an empiric iodine-131 therapy on the basis of improvements in various parameters of disease activity.</P>
<P>First, thyroglobulin levels measured after iodine-131 thyroid remnant ablation are a well-known marker of tumour course. An elevated thyroglobulin level correlates well with persistent disease (<LINK REF="STD-Pacini-2001" TYPE="STUDY">Pacini 2001</LINK>). Because the production of thyroglobulin and the incorporation of radioactive iodine represent distinct differentiated functions of follicular cells, differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases is suspected by the presence of detectable serum thyroglobulin in the absence of iodine-131 uptake. Serum thyroglobulin measurement is more sensitive than s diagnostic radioiodine whole body scan for the detection of recurrences and metastases (<LINK REF="REF-DeGroot-1990" TYPE="REFERENCE">DeGroot 1990</LINK>; <LINK REF="REF-Mazzaferri-2003" TYPE="REFERENCE">Mazzaferri 2003</LINK>; <LINK REF="REF-Sherman-1998" TYPE="REFERENCE">Sherman 1998</LINK>; <LINK REF="REF-van-den-Bergh-1993" TYPE="REFERENCE">van den Bergh 1993</LINK>), even in patients with negative radioiodine whole body scans (<LINK REF="REF-Brendel-1990" TYPE="REFERENCE">Brendel 1990</LINK>; <LINK REF="STD-Koh-2003" TYPE="STUDY">Koh 2003</LINK>; <LINK REF="REF-Pineda-1995" TYPE="REFERENCE">Pineda 1995</LINK>). A significant reduction in the thyroglobulin level can be obtained after iodine-131 therapy. In patients with positive thyroglobulin and negative radioiodine whole body scan, an elevation in the thyroglobulin level may be the first evidence (<LINK REF="REF-Black-1991" TYPE="REFERENCE">Black 1991</LINK>; <LINK REF="REF-Pineda-1993" TYPE="REFERENCE">Pineda 1993</LINK>; <LINK REF="REF-Sherman-1994" TYPE="REFERENCE">Sherman 1994</LINK>) or the only method by which metastatic or recurrent disease is detected (<LINK REF="REF-Schlumberger-1988" TYPE="REFERENCE">Schlumberger 1988</LINK>). Pacini et al (<LINK REF="STD-Pacini-2001" TYPE="STUDY">Pacini 2001</LINK>) compared the changes in serum thyroglobulin levels between treated and untreated patients with differentiated thyroid carcinoma; they noted a reduction in thyroglobulin levels and a disappearance of lung uptake with repeated therapy, and they recommended treating all patients with positive thyroglobulin and negative diagnostic radioiodine whole body scan once with 3700 MBq of radioactive iodine and continuing therapy until post-therapy whole body scan results become negative. Pineda et al (<LINK REF="REF-Pineda-1995" TYPE="REFERENCE">Pineda 1995</LINK>) noted that in a significant proportion of patients (50%), the therapeutic effectiveness of radioactive iodine treatment is indicated by a conversion to negative radioiodine whole body scan, a statistically significant decrease in the mean thyroglobulin level, and a reduction in the serum thyroglobulin level to 5 ng/mL or less. These studies suggest that empiric radioactive iodine therapy may be useful for diffuse lung uptake, especially in young and middle-aged patients with negative chest radiographs and diagnostic negative radioiodine whole body scans.</P>
<P>Second, a therapeutic dose of radioactive iodine increases the sensitivity of the radioiodine whole body scan and allows the detection of neoplastic foci not seen with a diagnostic dose of radioactive iodine (<LINK REF="REF-Cailleux-2000" TYPE="REFERENCE">Cailleux 2000</LINK>; <LINK REF="REF-Pacini-1987" TYPE="REFERENCE">Pacini 1987</LINK>; <LINK REF="STD-Pacini-2001" TYPE="STUDY">Pacini 2001</LINK>; <LINK REF="REF-Pineda-1993" TYPE="REFERENCE">Pineda 1993</LINK>; <LINK REF="REF-Schlumberger-1997" TYPE="REFERENCE">Schlumberger 1997</LINK>).</P>
<P>Third, the poor prognosis of patients with metastatic differentiated thyroid carcinoma will be improved if it is detected and treated with radioactive iodine early rather than late (<LINK REF="REF-Schlumberger-1999" TYPE="REFERENCE">Schlumberger 1999</LINK>). More importantly, radioactive iodine therapy is effective mostly in patients with small foci of recurrent disease. Negative radioiodine whole body scan was successfully treated with high doses of radioactive iodine after the administration of recombinant human thyroid stimulating hormone (<LINK REF="REF-Rudavsky-1997" TYPE="REFERENCE">Rudavsky 1997</LINK>). Controlled clinical studies are warranted to evaluate the safety and efficacy of recombinant human thyroid stimulating hormone in the radioactive iodine therapy of metastatic differentiated thyroid carcinoma.</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-11-05 15:37:52 +0100" MODIFIED_BY="Bernd Richter">
<P>For the time being, there is no consensus as to radioactive iodine therapy for thyroglobulin positive and radioactive iodine negative metastases in differentiated thyroid carcinoma. The use of radioiodine treatment has been associated with marked benefits. However, the quality and the effects of these trials have not been systematically reviewed and assessed. Therefore, this review aims to summarise the existing evidence of the comparative effects and safety of radioiodine treatment for thyroglobulin positive and radioactive iodine negative metastases.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of radioactive iodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-11 17:50:17 +0100" MODIFIED_BY="Bernd Richter">
<SELECTION_CRITERIA MODIFIED="2008-11-05 15:41:55 +0100" MODIFIED_BY="Bernd Richter">
<CRIT_STUDIES MODIFIED="2008-11-05 15:38:23 +0100" MODIFIED_BY="Bernd Richter">
<P>We planned to consider randomised controlled clinical trials and prospective controlled clinical trials with a duration of follow-up of at least one year.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-05 15:41:26 +0100" MODIFIED_BY="Bernd Richter">
<P>The diagnosis of differentiated thyroid carcinoma had to be established according to the definite pathophysiological evaluation of the surgical specimen.Trials which included patients of any age or sex who suffered from differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases after total or near-total thyroidectomy followed by iodine-131 remnant ablation and L-thyroxin suppression therapy were eligible. Patients with positive anti-thyroglobulin antibodies were excluded.</P>
<SUBSECTION>
<HEADING LEVEL="4">Diagnostic criteria</HEADING>
<P>The thyroglobulin value "off L-thyroxine therapy" equal to or greater than 10 ng/ml or "on L-thyroxine therapy" equal to or greater than 1 to 5 ng/ml (according to the sensitivity of the test) is defined as positive in the absence of circulating anti-thyroglobulin antibodies. The thyroglobulin value off "on-L-thyroxine therapy", equal to or less than 1 to 5 ng/ml (according to the sensitivity of the test) is regarded as undetectable in the absence of circulating anti-thyroglobulin autoantibodies.</P>
<P>Radioactive iodine negative metastases in all cases had to be established by the conventional whole body scan performed 48 to 72 hrs after administration of a tracer dose of 5 to 10 mCi radioactive iodine.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-05 15:41:55 +0100" MODIFIED_BY="Bernd Richter">
<P>Trials evaluating radioactive iodine treatment versus control interventions or no treatment.<BR/>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-05 12:23:00 +0100" MODIFIED_BY="Bernd Richter">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-05 12:22:46 +0100" MODIFIED_BY="Bernd Richter">
<UL>
<LI>survival rate at the end of follow-up;</LI>
</UL>
<UL>
<LI>tumour size at the end of follow-up;</LI>
</UL>
<UL>
<LI>adverse effects (for example, irradiation-induced genetic defects, infertility, carcinogenesis and leukemogenesis) (<LINK REF="REF-De-Keizer-2001" TYPE="REFERENCE">De Keizer 2001</LINK>; <LINK REF="REF-Hyer-2002" TYPE="REFERENCE">Hyer 2002</LINK>; <LINK REF="REF-Schlumberger-1998" TYPE="REFERENCE">Schlumberger 1998</LINK>) - the number of patients developing at least one severe adverse event listed above will be evaluated).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-05 12:23:00 +0100" MODIFIED_BY="Bernd Richter">
<UL>
<LI>serum thyroglobulin concentration at the end of follow-up or positive rate of post-therapy radioactive iodine whole body scan;</LI>
</UL>
<UL>
<LI>mortality related to differentiated thyroid carcinoma or iodine-131 within the duration of whole follow-up period and all-cause mortality;</LI>
</UL>
<UL>
<LI>healthy-related quality of life, ideally measured by using a validated instrument;</LI>
</UL>
<UL>
<LI>costs;</LI>
</UL>
<UL>
<LI>symptoms of hypothyroidism (for example, reproductive failure/infertility, myxoedema, tiredness, lethargy, slowing of mental function, cold intolerance, cardiac complications).</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-05 15:44:13 +0100" MODIFIED_BY="Bernd Richter">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-05 15:43:57 +0100" MODIFIED_BY="Bernd Richter">
<P>We used the following sources for the identification of trials:</P>
<UL>
<LI>
<I>The Cochrane Library </I>(issue 1, 2008);</LI>
<LI>MEDLINE (until May 2008);</LI>
<LI>EMBASE (until May 2008).</LI>
</UL>
<P>The described search strategy (for a detailed search strategy see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) was used for MEDLINE. For use with EMBASE and the other databases this strategy was slightly adapted. We also searched databases of ongoing trials: Current Controlled Trials (www.controlled-trials.com - with links to other databases of ongoing trials). </P>
<P>There were no language restrictions when searching for trials.</P>
<P>We searched the following web sites' references: International Council for the Control of differentiated thyroid carcinoma, Thyroid Disease Manager, and World Health Organization. In addition, we planned to contact trialists and other experts in the field for overlooked, unpublished or ongoing trials.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-05 15:44:13 +0100" MODIFIED_BY="Bernd Richter">
<P>We also hand searched the following journals for identification of trials:</P>
<UL>
<LI>Chinese Journal of Isotope (1989 to May 2008);</LI>
<LI>Radiological Pratice (1989 to May 2008);</LI>
<LI>Chinese Journal of Endocrinology and Metabolism (1984 to May 2008);</LI>
<LI>Chinese clinical trials and research database.</LI>
</UL>
<P>We also planned to identify additional studies by searching the reference lists of included trials and (systematic) reviews, meta-analyses and health-technology assessment reports noticed.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-11 17:50:17 +0100" MODIFIED_BY="Bernd Richter">
<STUDY_SELECTION MODIFIED="2008-11-05 15:45:14 +0100" MODIFIED_BY="Bernd Richter">
<P>To determine the studies to be assessed further, two authors (MC and XJW) independently scanned the abstract, titles or both sections of every record retrieved. All potentially relevant articles were investigated as full text. Interrater agreement for study selection will be measured using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Differences will be marked and if these studies are later on included, the influence of the primary choice will be subjected to a sensitivity analysis. Where differences in opinion exist, they will be resolved by a third party. If resolving disagreement is not possible, the article will be added to those 'awaiting assessment' and authors will be contacted for clarification. </P>
<P>An adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection was attached (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with duplicate publications</HEADING>
<P>In the case of duplicate publications and companion papers of a primary study, we planned to maximize yield of information by simultaneous evaluation of all available data. In cases of doubt, the original publication (usually the oldest version) obtained priority.</P>
</SUBSECTION>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-11 17:50:17 +0100" MODIFIED_BY="Bernd Richter">
<P>For studies that fulfilled inclusion criteria, two authors (MC and XJW) were planned to independently abstract relevant population and intervention characteristics using standard data extraction templates with any disagreements to be resolved by discussion, or if required by a third party. Any relevant missing information on the trial would have been sought from the original author(s) of the article, if required.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-11-05 13:02:02 +0100" MODIFIED_BY="Bernd Richter">
<P>We planned to assess the methodological quality of each trial in terms of generation of allocation sequence, allocation concealment, blinding, and loss to follow up; and classify them as 'adequate', 'inadequate', or 'unclear' according to the guidelines of <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Sensitivity analyses were planned to be undertaken on the basis of whether those quality factors were adequate, inadequate, or unclear. Differences were to be resolved by discussion among the review authors.</P>
<P>The following characteristics were assessed:</P>
<SUBSECTION>
<HEADING LEVEL="4">Adequacy of the randomization process</HEADING>
<P>A - adequate sequence generation is reported using one of following approaches: random number tables, computer-generated random numbers, coin tossing, or shuffling.<BR/>B - does not specify one of the adequate methods outlined in (A) but mentions the term 'random' only.<BR/>C - other methods of allocation that appear to be biased.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adequacy of the allocation concealment process</HEADING>
<P>A - adequate measures to conceal allocations such as central randomization, serially numbered, opaque, sealed envelopes, or another description that contains convincing elements of concealment.<BR/>B - unclearly-concealed trials in which the author do not report an allocation concealment approach at all.<BR/>C - inadequately-concealed allocation that reports an approach that does not fall into one of the categories in (A).<BR/>D - does not conceal allocation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Potential for selection bias after allocation</HEADING>
<P>A - trials where an intention-to-treat analysis is possible and few losses to follow up are noted.<BR/>B - trials which report exclusions, but exclusions were less than 10%.<BR/>C - no reporting on exclusions or exclusions of at least 10%, or wide differences in exclusions between groups.</P>
<P>Based on these criteria, studies will be broadly subdivided into the following three categories:<BR/>A - all quality criteria met (adequate): low risk of bias.<BR/>B - one or more of the quality criteria only partly met (unclear): moderate risk of bias.<BR/>C - one or more criteria not met (inadequate or not used): high risk of bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<MISSING_DATA MODIFIED="2008-11-05 15:46:18 +0100" MODIFIED_BY="Bernd Richter">
<P>Relevant missing data were planned to be obtained from authors, if feasible. Evaluation of important numerical data such as screened, eligible and randomised patients as well as intention-to-treat (ITT) and per-protocol (PP) population will be carefully performed. Attrition rates, for example drop-outs, losses to follow-up and withdrawals will be investigated. Issues of last-observation-carried-forward (LOCF), ITT and PP will be critically appraised and compared to specification of primary outcome parameters and power calculation.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-11-05 15:47:37 +0100" MODIFIED_BY="Bernd Richter">
<P>In the event of substantial clinical or methodological or statistical heterogeneity, study results will not be combined by means of meta-analysis. Heterogeneity will be identified by visual inspection of the forest plots, by using a standard I<SUP>2</SUP>-test and a significance level of &#945; = 0.1, in view of the low power of such tests. Heterogeneity will be specifically examined with I<SUP>2</SUP> (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>), where I<SUP>2</SUP> values of 50% and more indicate a substantial level of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). When heterogeneity is found, we will attempt to determine potential reasons for it by examining individual study characteristics and those of subgroups of the main body of evidence.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-11-05 12:31:02 +0100" MODIFIED_BY="Bernd Richter">
<P>Funnel plots were planned to be used in an exploratory data analysis to assess for the potential existence of small study bias. There are a number of explanations for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to study size, poor methodological design of small studies and publication bias (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). Therefore, results would have been interpreted with caution (<LINK REF="REF-Lau-2006" TYPE="REFERENCE">Lau 2006</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-05 15:49:14 +0100" MODIFIED_BY="Bernd Richter">
<P>If data are sufficiently similar, meta-analysis will be carried out using the Review Manager software. Statistical analysis will be performed according to the statistical guidelines referenced in the newest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Results will be expressed as risk ratios (RR) for dichotomous outcomes. Continuous outcomes will include mean differences (MD) or the standardized mean differences (SMD), both with 95% confidence intervals (CI). A fixed effect model will be used unless there is significant heterogeneity, in which case a random effects statistical model will be employed.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-11-05 15:49:34 +0100" MODIFIED_BY="Bernd Richter">
<P>Subgroup analysis was planned on regions of metastasis, treatment times, and sex of participants.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-11-05 15:50:01 +0100" MODIFIED_BY="Bernd Richter">
<P>We planned to perform sensitivity analyses in order to explore the influence of the following factors on effect size:<BR/>
</P>
<UL>
<LI>"repeating the analyses excluding any unpublished studies,</LI>
<LI>"repeating the analyses taking account of methodological study quality, as specified above,</LI>
<LI>"repeating the analyses excluding any very long or large studies to establish how much they dominate the results.</LI>
<LI>"repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>
<BR/>The robustness of the results will also tested by repeating the analyses using different measures of effect size (risk difference, odds ratio etc.) and different statistical models (fixed and random effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-05 15:51:10 +0100" MODIFIED_BY="Bernd Richter">
<STUDY_DESCRIPTION MODIFIED="2008-11-05 15:50:52 +0100" MODIFIED_BY="Bernd Richter">
<SEARCH_RESULTS MODIFIED="2008-11-05 15:50:52 +0100" MODIFIED_BY="Bernd Richter">
<P>The electronic searches and hand searches revealed 376 studies. Of these references, we excluded 373 citations. After reading the titles and abstracts, three potential controlled clinical trials were retrieved for further assessment. By reading the full article, we discovered that these were retrospective cohort studies (<LINK REF="STD-Koh-2003" TYPE="STUDY">Koh 2003</LINK>; <LINK REF="STD-Pacini-2001" TYPE="STUDY">Pacini 2001</LINK>; <LINK REF="STD-Tian-2003" TYPE="STUDY">Tian 2003</LINK>). </P>
<P>For an overview (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), please see the adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>).</P>
</SEARCH_RESULTS>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-05 15:51:02 +0100" MODIFIED_BY="Bernd Richter">
<P>Not possible.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-05 15:51:10 +0100" MODIFIED_BY="Bernd Richter">
<P>In the absence of any suitable controlled trials in this area, we were unable to perform any analysis.<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-05 15:55:45 +0100" MODIFIED_BY="Bernd Richter">
<P>No evidence from randomised or prospective controlled trials for or against radioactive iodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases based on the retrieved studies was available.</P>
<P>Current study data from uncontrolled trials regarding radioiodine versus no radioiodine treatment suggest that radioiodine treatment has a therapeutic effect when thyroglobulin level is considered an index of tumour burden. Further prospective controlled trials of high-quality and large scale are urgently needed in order to define the effectiveness and acceptability of radioiodine treatment.</P>
<P>Dada from the three excluded retrospective cohort trials (<LINK REF="STD-Koh-2003" TYPE="STUDY">Koh 2003</LINK>; <LINK REF="STD-Pacini-2001" TYPE="STUDY">Pacini 2001</LINK>; <LINK REF="STD-Tian-2003" TYPE="STUDY">Tian 2003</LINK>, ) revealed that the administration of therapeutic doses of iodine-131 has therapeutic effects, at least for palliation in the short-term, and could localize previously undiagnosed recurrence in some patients with differentiated thyroid cancer who show an elevated thyroglobulin level but negative diagnostic iodine-131 whole-body scan. Another author (<LINK REF="REF-Chao-2005_x002d_2" TYPE="REFERENCE">Chao 2005-2</LINK>) reviewed ten case series and three trials relevant to patients with positive thyroglobulin and negative diagnostic radioiodine whole body scintigraphy. A decrease in thyroglobulin levels was achieved in 63% of 314 patients with thyroglobulin positive and negative diagnostic radioiodine whole body scintigraphy metastases, which suggested that radioiodine therapy has a therapeutic effect when the thyroglobulin level is considered an index of tumour burden. Therefore, radioiodine treatment may be justified in high risk patients with thyroglobulin levels of above 10 ng/L and negative body scan.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-05 15:57:10 +0100" MODIFIED_BY="Bernd Richter">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-05 15:56:05 +0100" MODIFIED_BY="Bernd Richter">
<P>There is currently no firm evidence for or against radioactive iodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-05 15:57:10 +0100" MODIFIED_BY="Bernd Richter">
<P>Rigorously designed prospective, controlled clinical trials are required to evaluate radioactive iodine treatment for differentiated thyroid carcinoma patients with thyroglobulin positive and radioactive iodine negative metastases. The authors should at least report the outcomes on survival rate and tumour size. Adverse events should be critically assessed by standardized monitoring or an effective self-report system and attention should be paid to long-term adverse effects of radioiodine in larger populations.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-11-05 12:14:17 +0100" MODIFIED_BY="Bernd Richter">
<P>We thank Dr. Wu Taixiang and Wu Bo from the Evidence-based Center West China Hospitalfor their invaluable help throughout the review and we are most grateful to them for their advice and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-05 15:57:17 +0100" MODIFIED_BY="Bernd Richter">
<P>ANREN KUANG: drafting and co-drafting of the protocol and review.<BR/>GUANJIAN LIU: assistance with statistics and review draft.<BR/>TIEKUN MA: searching, selection of studies.<BR/>CHAO MA: data extraction, data analysis and data presentation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-05 15:36:40 +0100" MODIFIED_BY="Bernd Richter">
<STUDIES MODIFIED="2008-11-05 12:50:07 +0100" MODIFIED_BY="Bernd Richter">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2008-11-05 12:50:07 +0100" MODIFIED_BY="Bernd Richter">
<STUDY DATA_SOURCE="PUB" ID="STD-Koh-2003" MODIFIED="2008-11-05 12:49:38 +0100" MODIFIED_BY="Bernd Richter" NAME="Koh 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-05 12:49:38 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koh JM, Kim ES, Ryu JS, et al</AU>
<TI>Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study</TI>
<SO>Clinical Endocrinology</SO>
<YR>2003</YR>
<VL>58</VL>
<PG>421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pacini-2001" MODIFIED="2008-11-05 12:49:57 +0100" MODIFIED_BY="Bernd Richter" NAME="Pacini 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-05 12:49:57 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pacini L, Agate R, Elisei M</AU>
<TI>Outcome of differentiated thyroid cancer with detectable serum Thyroglobulin and negative 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2001</YR>
<VL>86</VL>
<PG>4092-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-2003" MODIFIED="2008-11-05 12:50:07 +0100" MODIFIED_BY="Bernd Richter" NAME="Tian 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-05 12:50:07 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tian R, Pan M, Kuang A</AU>
<TI>Evaluation of I-131 therapy for differentiated thyroid carcinoma patients with elevated thyroglobulin and negative I-131whole body scan</TI>
<SO>Chinese Journal of Nuclear Medicine</SO>
<YR>2003</YR>
<VL>23</VL>
<PG>27-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-05 15:36:40 +0100" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-05 15:36:40 +0100" MODIFIED_BY="Bernd Richter">
<REFERENCE ID="REF-Alexande-1998" MODIFIED="2008-11-05 12:40:49 +0100" MODIFIED_BY="Bernd Richter" NAME="Alexande 1998" TYPE="JOURNAL_ARTICLE">
<AU>Alexander C, Bader JB, Schaefer A, et al</AU>
<TI>Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma</TI>
<SO>J Nucl Med</SO>
<YR>1998</YR>
<VL>39</VL>
<PG>1551-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-1991" MODIFIED="2008-11-05 12:41:19 +0100" MODIFIED_BY="Bernd Richter" NAME="Black 1991" TYPE="JOURNAL_ARTICLE">
<AU>Black EG, Sheppard MC</AU>
<TI>Serum thyroglobulin measurements in thyroid cancer: evaluation of false positive results</TI>
<SO>Clin Endocrinol (Oxford)</SO>
<YR>1991</YR>
<VL>35</VL>
<PG>519</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brendel-1990" MODIFIED="2008-11-05 12:41:28 +0100" MODIFIED_BY="Bernd Richter" NAME="Brendel 1990" TYPE="JOURNAL_ARTICLE">
<AU>Brendel AJ, Lambert B, Guyot M, et al</AU>
<TI>Low levels of serum thyroglobulin after withdrawl of thyroid suppression therapy in the follow-up of differentiated thyroid carcinoma</TI>
<SO>European Journal of Nuclear Medicine</SO>
<YR>1990</YR>
<VL>16</VL>
<PG>35-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cailleux-2000" MODIFIED="2008-11-05 12:41:39 +0100" MODIFIED_BY="Bernd Richter" NAME="Cailleux 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger MJ</AU>
<TI>Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?</TI>
<SO>Clin Endocrinol Metab</SO>
<YR>2000</YR>
<VL>85</VL>
<PG>175-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chao-2005_x002d_1" MODIFIED="2008-11-05 12:41:51 +0100" MODIFIED_BY="Bernd Richter" NAME="Chao 2005-1" TYPE="JOURNAL_ARTICLE">
<AU>Chao Ma, Anren Kuang, Jiawei Xie, et al</AU>
<TI>The Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-body Scan</TI>
<SO>J Nucl Med</SO>
<YR>2005</YR>
<VL>46</VL>
<PG>1473-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chao-2005_x002d_2" MODIFIED="2008-11-05 12:42:14 +0100" MODIFIED_BY="Bernd Richter" NAME="Chao 2005-2" TYPE="JOURNAL_ARTICLE">
<AU>Chao Ma, Jiawei Xie, Anren Kuang</AU>
<TI>Is Blind 131I Therapy Justified for Patients with Negative Tg and Positive 131I W</TI>
<SO>J Nucl Med</SO>
<YR>2005</YR>
<VL>46</VL>
<PG>1164-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2002" MODIFIED="2008-11-05 12:42:22 +0100" MODIFIED_BY="Bernd Richter" NAME="Clark 2002" TYPE="JOURNAL_ARTICLE">
<AU>Clark PM, Beckett G</AU>
<TI>Can we measure serum thyroglobulin? Annals of clinical biochemistry</TI>
<SO>Annals of clinical biochemistry</SO>
<YR>2002</YR>
<VL>39</VL>
<PG>196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" MODIFIED="2008-11-05 12:42:28 +0100" MODIFIED_BY="Bernd Richter" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Keizer-2001" MODIFIED="2008-11-05 12:42:34 +0100" MODIFIED_BY="Bernd Richter" NAME="De Keizer 2001" TYPE="JOURNAL_ARTICLE">
<AU>De Keizer B, Koppeschaar HP, Zelissen PM, et al</AU>
<TI>Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin.</TI>
<SO>Europe Journal of Nuclear Medicine</SO>
<YR>2001</YR>
<VL>28</VL>
<PG>198 -202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Vathaire-1997" MODIFIED="2008-11-05 12:42:43 +0100" MODIFIED_BY="Bernd Richter" NAME="de Vathaire 1997" TYPE="JOURNAL_ARTICLE">
<AU>de Vathaire F, Schlumberger M, Delisle MJ</AU>
<TI>Leukaemias and cancers following iodine-131 administration for thyroid cancer.</TI>
<SO>Br J Cancer</SO>
<YR>1997</YR>
<VL>75</VL>
<PG>734 -9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeGroot-1990" MODIFIED="2008-11-05 12:42:53 +0100" MODIFIED_BY="Bernd Richter" NAME="DeGroot 1990" TYPE="JOURNAL_ARTICLE">
<AU>DeGroot LJ, Kaplan EL, McCormick M, et al</AU>
<TI>Natural history, treatment, and course of papillary thyroid carcinoma.</TI>
<SO>J Clin Endocrinol Metab</SO>
<YR>1990</YR>
<VL>71</VL>
<PG>414</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fatourech-2002" MODIFIED="2008-11-05 12:43:02 +0100" MODIFIED_BY="Bernd Richter" NAME="Fatourech 2002" TYPE="JOURNAL_ARTICLE">
<AU>Fatourech V, Hay ID, Javedan H, Wiseman G.A. Mullan B P, Gorman C A</AU>
<TI>Lack of impact of radioiodine therapy in Thyroglobulinpositive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<PG>1521-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fatourechi-2000" MODIFIED="2008-11-05 15:35:49 +0100" MODIFIED_BY="Bernd Richter" NAME="Fatourechi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fatourechi V, Hay ID.</AU>
<TI>Treating the patients with differentiated thyroid cancer with thyroglobulin-positive surveillance</TI>
<SO>Seminars in Nuclear Medicine</SO>
<YR>2000</YR>
<VL>25</VL>
<PG>443-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2008-11-05 12:43:20 +0100" MODIFIED_BY="Bernd Richter" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-11-05 12:43:25 +0100" MODIFIED_BY="Bernd Richter" NAME="Higgins 2003" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holzer-2000" MODIFIED="2008-11-05 15:33:59 +0100" MODIFIED_BY="Bernd Richter" NAME="Holzer 2000" TYPE="JOURNAL_ARTICLE">
<AU>Holzer S, Reiners C, Mann K, Bamberg M, Rothmund M, Dudeck J, Stewart AK, Hundahl SA</AU>
<TI>Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996.US and German Thyroid Cancer Group</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>89</VL>
<PG>192-201</PG>
<IDENTIFIERS MODIFIED="2008-11-05 15:33:34 +0100" MODIFIED_BY="Bernd Richter">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hundahl-2000" MODIFIED="2008-11-05 12:44:11 +0100" MODIFIED_BY="Bernd Richter" NAME="Hundahl 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S</AU>
<TI>Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996,US and German Thyroid Cancer Study Group.An American College of Surgeons Commission on Cancer Patient Care Evaluation study</TI>
<SO>Cancer</SO>
<YR>2000</YR>
<VL>89</VL>
<PG>202-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hyer-2002" MODIFIED="2008-11-05 15:36:18 +0100" MODIFIED_BY="Bernd Richter" NAME="Hyer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hyer S, Vini L, O'Connell M, et al</AU>
<TI>Testicular dose and fertility in men following 131therapy for thyroid cancer</TI>
<SO>Clinical Endocrinology</SO>
<YR>2002</YR>
<VL>56</VL>
<PG>755-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-2006" MODIFIED="2008-11-05 12:44:32 +0100" MODIFIED_BY="Bernd Richter" NAME="Lau 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I</AU>
<TI>Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma</TI>
<SO>Journal of Nuclear Medicine</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>257-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mackenzie-2004" MODIFIED="2008-11-05 12:44:43 +0100" MODIFIED_BY="Bernd Richter" NAME="Mackenzie 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mackenzie EJ, Mortimer RH</AU>
<TI>Thyroid nodules and thyroid cancer</TI>
<SO>The Medical Journal of Australia</SO>
<YR>2004</YR>
<VL>180</VL>
<PG>242-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maxon-1983" MODIFIED="2008-11-05 12:44:52 +0100" MODIFIED_BY="Bernd Richter" NAME="Maxon 1983" TYPE="JOURNAL_ARTICLE">
<AU>Maxon HR, Thomas SR, Boehringer A, et al</AU>
<TI>Low iodine diet in I-131 ablation of thyroid remnants</TI>
<SO>Clinical Nuclear Medicine</SO>
<YR>1983</YR>
<VL>8</VL>
<PG>123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazzaferri-2001" MODIFIED="2008-11-05 12:45:12 +0100" MODIFIED_BY="Bernd Richter" NAME="Mazzaferri 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mazzaferri EL, Kloos RT</AU>
<TI>Current approaches to primary therapy for papillary and follicular thyroid cancer</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2001</YR>
<VL>86</VL>
<PG>1447-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazzaferri-2003" MODIFIED="2008-11-05 12:45:24 +0100" MODIFIED_BY="Bernd Richter" NAME="Mazzaferri 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mazzaferri EL, Robbins RJ, Spence CA, et al.</AU>
<TI>A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.</TI>
<SO>J Clin Endocrinol Metab</SO>
<YR>2003</YR>
<VL>88</VL>
<PG>1433-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDougall-1997" MODIFIED="2008-11-05 12:45:31 +0100" MODIFIED_BY="Bernd Richter" NAME="McDougall 1997" TYPE="JOURNAL_ARTICLE">
<AU>McDougall IR</AU>
<TI>131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?</TI>
<SO>Thyroid</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>669-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mertens-1999" MODIFIED="2008-11-05 12:45:38 +0100" MODIFIED_BY="Bernd Richter" NAME="Mertens 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mertens IJ, De Klerk JM, Zelissen PM, et al</AU>
<TI>Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer</TI>
<SO>Clinical Nuclear Medicine</SO>
<YR>1999</YR>
<VL>24</VL>
<PG>346-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" MODIFIED="2008-11-05 12:45:42 +0100" MODIFIED_BY="Bernd Richter" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S,et al</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement.Quality of Reporting of Meta-analyses.</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muller_x002d_Gartner-1988" MODIFIED="2008-11-05 12:45:55 +0100" MODIFIED_BY="Bernd Richter" NAME="Muller-Gartner 1988" TYPE="JOURNAL_ARTICLE">
<AU>Muller-Gartner HW, Schneider C</AU>
<TI>Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer</TI>
<SO>Cancer</SO>
<YR>1988</YR>
<VL>61</VL>
<PG>976-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ozata-1994" MODIFIED="2008-11-05 15:36:40 +0100" MODIFIED_BY="Bernd Richter" NAME="Ozata 1994" TYPE="JOURNAL_ARTICLE">
<AU>Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ</AU>
<TI>Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1994</YR>
<VL>79</VL>
<PG>98-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pacini-1987" MODIFIED="2008-11-05 12:46:25 +0100" MODIFIED_BY="Bernd Richter" NAME="Pacini 1987" TYPE="JOURNAL_ARTICLE">
<AU>Pacini F, Lippi F, Formica N, et al</AU>
<TI>Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels</TI>
<SO>Journal of Nuclear Medicine</SO>
<YR>1987</YR>
<VL>28</VL>
<PG>1888-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pacini-1999" MODIFIED="2008-11-05 12:46:29 +0100" MODIFIED_BY="Bernd Richter" NAME="Pacini 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pacini F, Pinchera A</AU>
<TI>Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease</TI>
<SO>Biochimie</SO>
<YR>1999</YR>
<VL>81</VL>
<PG>463-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pineda-1993" MODIFIED="2008-11-05 12:46:40 +0100" MODIFIED_BY="Bernd Richter" NAME="Pineda 1993" TYPE="JOURNAL_ARTICLE">
<AU>Pineda JD, Lee T, Robbins J</AU>
<TI>Treating metastatic thyroid cancer</TI>
<SO>Endocrinologist</SO>
<YR>1993</YR>
<VL>3</VL>
<PG>433-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pineda-1995" MODIFIED="2008-11-05 12:46:58 +0100" MODIFIED_BY="Bernd Richter" NAME="Pineda 1995" TYPE="JOURNAL_ARTICLE">
<AU>Pineda JD, Lee T, Ain K, et al</AU>
<TI>Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan</TI>
<SO>The Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1995</YR>
<VL>80</VL>
<PG>1488-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudavsky-1997" MODIFIED="2008-11-05 12:47:07 +0100" MODIFIED_BY="Bernd Richter" NAME="Rudavsky 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rudavsky AZ, Freeman LM</AU>
<TI>Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone</TI>
<SO>J Clin Endocrinol Metab</SO>
<YR>1997</YR>
<VL>82</VL>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Samaan-1985" MODIFIED="2008-11-05 12:47:11 +0100" MODIFIED_BY="Bernd Richter" NAME="Samaan 1985" TYPE="JOURNAL_ARTICLE">
<AU>Samaan NA, Schultz PN, Haynie TP, Ordonez NG</AU>
<TI>Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients</TI>
<SO>The Journal of clinical endocrinology and metabolism</SO>
<YR>1985</YR>
<VL>60</VL>
<PG>376-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schlumberger-1988" MODIFIED="2008-11-05 12:47:16 +0100" MODIFIED_BY="Bernd Richter" NAME="Schlumberger 1988" TYPE="JOURNAL_ARTICLE">
<AU>Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C</AU>
<TI>Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-ray.</TI>
<SO>Journal of Nuclear Medicine</SO>
<YR>1988</YR>
<VL>29</VL>
<PG>1790-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schlumberger-1997" MODIFIED="2008-11-05 12:47:22 +0100" MODIFIED_BY="Bernd Richter" NAME="Schlumberger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Schlumberger M, Mancusi F, Baudin E, et al</AU>
<TI>131-I therapy for elevated thyroglobulin levels</TI>
<SO>Thyroid</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>273-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schlumberger-1998" MODIFIED="2008-11-05 12:47:33 +0100" MODIFIED_BY="Bernd Richter" NAME="Schlumberger 1998" TYPE="JOURNAL_ARTICLE">
<AU>Schlumberger MJ</AU>
<TI>Papillary and follicular thyroid carcinoma</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>297-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schlumberger-1999" MODIFIED="2008-11-05 12:47:42 +0100" MODIFIED_BY="Bernd Richter" NAME="Schlumberger 1999" TYPE="JOURNAL_ARTICLE">
<AU>Schlumberger MJ</AU>
<TI>Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status</TI>
<SO>J Endocrinol Invest</SO>
<YR>1999</YR>
<VL>22(suppl 11)</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherman-1994" MODIFIED="2008-11-05 12:47:47 +0100" MODIFIED_BY="Bernd Richter" NAME="Sherman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Sherman SI, Tielens ET, Sostre S, et al</AU>
<TI>Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma</TI>
<SO>The Journal of clinical endocrinology and metabolism</SO>
<YR>1994</YR>
<VL>78</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherman-1998" MODIFIED="2008-11-05 12:47:58 +0100" MODIFIED_BY="Bernd Richter" NAME="Sherman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sherman SI, Brierley JD, Sperling M, et al</AU>
<TI>Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry</TI>
<SO>Cancer</SO>
<YR>1998</YR>
<VL>83</VL>
<PG>1012-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spencer-1996" MODIFIED="2008-11-05 12:48:10 +0100" MODIFIED_BY="Bernd Richter" NAME="Spencer 1996" TYPE="JOURNAL_ARTICLE">
<AU>Spencer CA, Takeuchi M, Kazarosyan M</AU>
<TI>Current Status and Performance Goals for Serum Thyroglobulin Assays</TI>
<SO>Clinical Chemistry</SO>
<YR>1996</YR>
<VL>42</VL>
<PG>164-173</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2008-11-05 12:48:21 +0100" MODIFIED_BY="Bernd Richter" NAME="Sterne 2001" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Davey Smith G</AU>
<TI>Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG, editors(s)</TI>
<SO>Systematic Reviews in Health Care; Meta-analysis in Context., London: BMJ Publishing Group</SO>
<YR>2001</YR>
<PG>189-208</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stojadinovic-2001" MODIFIED="2008-11-05 12:48:32 +0100" MODIFIED_BY="Bernd Richter" NAME="Stojadinovic 2001" TYPE="JOURNAL_ARTICLE">
<AU>Stojadinovic A, Ghossein RA, Hoos A, Ronald A, Marshall J, Ronald H, et al</AU>
<TI>Hurtle cell carcinoma: A critical histopathologic appraisal</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>2616-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tenenbaum-1996" MODIFIED="2008-11-05 12:48:39 +0100" MODIFIED_BY="Bernd Richter" NAME="Tenenbaum 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tenenbaum F, Corone C, Schlumberger M, Parmentier C</AU>
<TI>Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease [abstract]</TI>
<SO>Eur J Cancer</SO>
<YR>1996</YR>
<VL>32A</VL>
<PG>1262</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-den-Bergh-1993" MODIFIED="2008-11-05 12:49:06 +0100" MODIFIED_BY="Bernd Richter" NAME="van den Bergh 1993" TYPE="JOURNAL_ARTICLE">
<AU>van den Bergh JP, Pieters GF, Beex LV, et al</AU>
<TI>Compared to whole body scanning thyroglobulin assay is reliable in the follow-up of thyroidectomized patients with thyroid carcinoma</TI>
<SO>Ned Tijdschr Geneeskd</SO>
<YR>1993</YR>
<VL>137</VL>
<PG>1344-1348</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Tol-2003" MODIFIED="2008-11-05 12:49:12 +0100" MODIFIED_BY="Bernd Richter" NAME="Van Tol 2003" TYPE="JOURNAL_ARTICLE">
<AU>Van Tol KM, Jager PL, De Vries EG, et al</AU>
<TI>Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin</TI>
<SO>Europe Journal of Endocrinololy</SO>
<YR>2003</YR>
<VL>148</VL>
<PG>589-96</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-05 12:13:36 +0100" MODIFIED_BY="Bernd Richter">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-05 12:13:36 +0100" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-05 12:13:19 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Koh-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-05 12:13:19 +0100" MODIFIED_BY="Bernd Richter">
<P>retrospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-05 12:13:34 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Pacini-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-05 12:13:34 +0100" MODIFIED_BY="Bernd Richter">
<P>retrospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-05 12:13:36 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Tian-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-05 12:13:36 +0100" MODIFIED_BY="Bernd Richter">
<P>retrospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-05 12:57:23 +0100" MODIFIED_BY="Bernd Richter"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-05 12:12:25 +0100" MODIFIED_BY="Bernd Richter"/>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-05 15:37:11 +0100" MODIFIED_BY="Bernd Richter">
<APPENDIX ID="APP-01" MODIFIED="2008-11-05 15:37:11 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2008-11-05 12:56:47 +0100" MODIFIED_BY="Bernd Richter">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-05 15:37:11 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Notes: Unless otherwise stated, search terms were free text terms; exp = exploded<BR/>MeSH: Medical Subject Heading (Medline medical index term); the dollar sign ($)<BR/>stands for any character(s); the question mark (?) = substitute for one or no<BR/>characters; ab = abstract; ti = title; ot = original title; pt = publication type; sh =<BR/>MeSH: Medical subject heading (MEDLINE medical index term); adj = adjacency.</P>
<P/>
<P>1.exp Thyroid Neoplasms/<BR/>2.((thyroid carcinom$ or thyroid neoplasm$) adj different$).tw.<BR/>3.(different$ adj (thyroid carcinom$ or thyroid neoplasm$)).tw.<BR/>
</P>
<P>4.or/1-3</P>
<P>5.radioactiv$ iodin$.tw.<BR/>6.iodine?131.tw.<BR/>7.iodin$ 131.tw.<BR/>8.radioiodin$.tw.<BR/>9.thyreoglobulin$.tw.</P>
<P>10.or/ 5-9<BR/>11.4 and 10<BR/>12.limit 11 to human</P>
<P>13.randomized controlled trial.pt.<BR/>14.controlled clinical trial.pt.<BR/>15.randomized controlled trials.sh.<BR/>16.random allocation.sh.<BR/>17.double-blind method.sh.<BR/>18.single-blind method.sh.</P>
<P>19.or/ 13-18<BR/>20.limit 19 to animal<BR/>21.limit 19 to human<BR/>22.20 not 21<BR/>23.19 not 22</P>
<P>24.clinical trial.pt.<BR/>25.exp clinical trials/<BR/>26.(clinic$ adj25 trial$).tw.<BR/>27.((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.<BR/>28.placebos.sh.<BR/>29.placebo$.tw.<BR/>30.random$.tw.</P>
<P>45.limit 44 to animal31.research design.sh.</P>
<P>32.(latin adj square).tw.<BR/>33.or/ 24-32</P>
<P>34.limit 33 to animal<BR/>35.limit 33 to human<BR/>36.34 not 35<BR/>37.33 not 36</P>
<P>38.comparative study.pt.<BR/>39.exp evaluation studies/<BR/>40.follow-up studies.sh.<BR/>41.prospective studies.sh.<BR/>42.(control$ or prospectiv$ or volunteer$).tw.<BR/>43.cross-over studies.sh.</P>
<P>44.or/ 38-43<BR/>45.limit 44 to animal<BR/>46.limit 44 to human</P>
<P/>
<P>47.45 not 46<BR/>48.44 not 47<BR/>49.23 or 37 or 48<BR/>50.12 and 49</P>
<P>51.exp "Review Literature"/<BR/>52.exp Technology Assessment, Biomedical/<BR/>53.exp Meta-Analysis/<BR/>54.meta-analysis.pt.<BR/>55.((review$ or search$) adj10 (literature or medical database$ or medline or<BR/>pubmed or embase or cochrane or cinhal or psychinfo or psychlit or healthstar or biosis or<BR/>current content$ or systemat$)).tw,kf,ot.<BR/>56.hta.tw,kf,ot.<BR/>57.(health technology adj6 assessment$).tw,kf,ot.<BR/>58.(meta analy$ or metaanly$ or meta?analy$).tw,kf,ot.<BR/>
</P>
<P>59.or/33-40<BR/>60. 12 and 59<BR/>61. 50 or 60</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>